Physician profile
Bisena Bulica
NPI 1093152019
$900,348.07
in general payments reported to CMS, 2019-2025
35 companies · $272K in 2025
The $272K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,651 · 2020: $2,133 · 2021: $55K · 2022: $182K · 2023: $180K · 2024: $205K · 2025: $272K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $426K · Consulting Fee: $106K · Travel and Lodging: $84K · Food and Beverage: $34K · Honoraria: $4,660 · Education: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $426,190.63 |
| Consulting Fee | $106,417.50 |
| Travel and Lodging | $84,044.10 |
| Food and Beverage | $33,605.81 |
| Honoraria | $4,660.00 |
| Education | $1,834.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $580,556.79 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $212,417.27 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $35,499.22 | 2019-2025 | Nuplazid |
| Kyowa Kirin, INC. | $15,466.61 | 2019-2024 | Nourianz |
| Boston Scientific Corporation | $9,255.84 | 2019-2025 | Vercise |
| Abbvie INC. | $9,173.55 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Amneal Pharmaceuticals LLC | $7,267.89 | 2024-2025 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Medtronic, INC. | $6,873.30 | 2021-2025 | Percept Pc Brainsense, Activa Pc |
| Merz Pharmaceuticals, LLC | $5,205.06 | 2024-2025 | Xeomin, Inbrija |
| Mdd US Operations, LLC | $4,323.39 | 2020-2025 | Gocovri, Apokyn |
| Roche Products Limited | $3,685.39 | 2023-2025 | |
| Abbott Laboratories | $3,361.48 | 2019-2025 | Infinity |
| Eisai INC. | $1,073.43 | 2019-2025 | |
| Allergan, INC. | $623.75 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $611.29 | 2022-2025 | Qelbree |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $557.11 | 2019-2022 | |
| Medtronic USA, INC. | $538.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $470.22 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $447.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $416.04 | 2019-2025 | |
| Revance Therapeutics, INC. | $362.16 | 2024-2025 | Daxxify |
| Acorda Therapeutics, INC | $270.80 | 2019-2024 | Inbrija |
| Ucb, INC. | $256.15 | 2020-2023 | Nayzilam |
| Catalyst Pharmaceuticals, INC. | $247.50 | 2024 | |
| Jazz Pharmaceuticals INC. | $246.82 | 2022-2024 | |
| Greenwich Biosciences, INC. | $237.25 | 2019 | |
| Genentech, INC. | $170.23 | 2023-2024 | Evrysdi |
| Insightec,INC | $167.55 | 2025 | Exablate |
| Ipsen Biopharmaceuticals, INC | $150.01 | 2019-2025 | Dysport |
| Pfizer INC. | $140.90 | 2024-2025 | |
| Sk Life Science, INC. | $122.05 | 2021 | |
| Neurelis, INC. | $99.22 | 2024 | Valtoco |
| Ricoh USA, INC | $53.03 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bisena Bulica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.